Primary systemic vasculitis with severe α1-antitrypsin deficiency revisited

被引:9
|
作者
Mohammad, A. [1 ,2 ]
Segelmark, M. [3 ,4 ]
机构
[1] Lund Univ, Dept Clin Sci, Rheumatol Sect, Lund, Sweden
[2] Skane Univ Hosp, Dept Rheumatol, SE-22185 Lund, Sweden
[3] Cty Council Ostergotland, Dept Nephrol UHL, Linkoping, Sweden
[4] Linkoping Univ, Dept Med & Hlth Sci, S-58183 Linkoping, Sweden
关键词
ANCA-ASSOCIATED VASCULITIS; DAMAGE INDEX VDI; ALPHA-1-ANTITRYPSIN DEFICIENCY; WEGENERS-GRANULOMATOSIS; POLYARTERITIS-NODOSA; ANTITRYPSIN;
D O I
10.3109/03009742.2013.846405
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: To study the clinical characteristics and epidemiology of the combination of primary systemic vasculitis (PSV) and severe alpha-1 antitrypsin (alpha(1)-AT) deficiency. Method: Patients with PSV [granulomatosis with polyangiitis (GPA) (Wegener's), microscopic polyangiitis, eosinophilic granulomatosis with polyangiitis (EGPA) (Churg-Strauss), and polyarteritis nodosa] were identified through diagnosis registries and serological databases. Clinical and laboratory data, including the presence of severe alpha(1)-AT deficiency, were collected from the time of diagnosis. During follow-up, data on relapses and permanent organ damage were collected. Using the county of Skane as the denominator population, we estimated the annual incidence rate and point prevalence of PSV in people with severe alpha(1)-AT deficiency. Results: Five patients (three women, median age 49 years) with PSV diagnosed between 1996 and 2008 were found to have alpha(1)-AT deficiency, all of them carrying the protease inhibitor ZZ (PiZZ) phenotype. During follow-up (median time 166 months, range 53-208), four patients experienced a total of 13 relapses. The median Vasculitis Damage Index (VDI) score for all patients was 3 (range 1-4) at year 1, and 7 (range 3-9) at the last follow-up. The incidence rate of PSV among PiZZ carriers was estimated to be 397/million [95% confidence interval (CI) 8-787]. The point prevalence on 1 January 2013 was estimated to be 4689/million (95% CI 94-9285). Conclusions: In this study both the incidence and prevalence of PSV were elevated nearly 10-fold for individuals with severe alpha(1)-AT deficiency compared with the general population. Combined with previous publications, this indicates a dose-response relationship for the genetic risk and suggests a causal relationship between the PiZ allele and vasculitis.
引用
收藏
页码:242 / 245
页数:4
相关论文
共 50 条
  • [41] Survival and FEV1 decline in individuals with severe deficiency of α1-antitrypsin
    Vreim, CE
    Wu, M
    Crystal, RG
    Buist, AS
    Burrows, B
    Cohen, AB
    Fallat, RJ
    Gadek, JE
    Rousell, RH
    Schwartz, RS
    Turino, GM
    Schluchter, MD
    Stoller, JK
    Wiedemann, HP
    Williams, GW
    Barrett, DM
    Beck, GJ
    McCarthy, K
    Midcalf, V
    Moore, B
    Sartori, P
    Sherer, SG
    Zhang, R
    Petty, TL
    Tomashefski, JF
    Brantly, ML
    Hildesheim, J
    Rundquist, B
    Sandhaus, RA
    Bell, CW
    Berend, J
    Ravikrishnan, KP
    Begle, R
    Erb, D
    Seidman, J
    Sherman, S
    Cameron, B
    Weinberger, S
    Rosenberg, M
    Johnston, R
    Arroliga, AC
    Meeker, DP
    Mehta, A
    Laskowski, D
    Ryan, WJ
    Loftin, JP
    Johnson, K
    Kotch, A
    Clark, T
    Epstein, PE
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1998, 158 (01) : 49 - 59
  • [42] The bronchopulmonary pathology of alpha 1-antitrypsin (AAT) deficiency: Findings of the death review Committee of the National Registry for Individuals with Severe Deficiency of Alpha 1-antitrypsin
    Tomashefski, JF
    Crystal, RG
    Wiedemann, HP
    Mascha, E
    MODERN PATHOLOGY, 2003, 16 (01) : 315A - 315A
  • [43] α1-Antitrypsin deficiency: A pediatric perspective
    Schwerk N.
    Kardorff R.
    Der Pneumologe, 2010, 7 (5): : 365 - 369
  • [44] Successful α1-antitrypsin replacement therapy in a patient with α1-antitrypsin deficiency and granulomatosis with polyangiitis
    Hernandez Perez, Jose Maria
    Garcia, Sergio Fumero
    Pio, Alberto Alvarez
    RHEUMATOLOGY, 2013, 52 (04) : 755 - 757
  • [45] The selective advantage of α1-antitrypsin deficiency
    Lomas, DA
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2006, 173 (10) : 1072 - 1077
  • [46] α1-antitrypsin deficiency and Pi typing
    Barlow, Ian
    Sewell, W. A. Carrock
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2008, 122 (03) : 658 - 658
  • [47] Augmentation therapy in α1-antitrypsin deficiency
    Burdon, JGW
    Brenton, S
    Ayad, M
    Knight, K
    CHEST, 2001, 120 (02) : 687 - 687
  • [48] Augmentation therapy for α1-antitrypsin deficiency
    Juvelekian, GS
    Stoller, JK
    DRUGS, 2004, 64 (16) : 1743 - 1756
  • [49] Author Correction: α1-Antitrypsin deficiency
    Catherine M. Greene
    Stefan J. Marciniak
    Jeffrey Teckman
    Ilaria Ferrarotti
    Mark L. Brantly
    David A. Lomas
    James K. Stoller
    Noel G. McElvaney
    Nature Reviews Disease Primers, 4 (1)
  • [50] Pneumothorax Associated with α1-Antitrypsin Deficiency
    Kanazawa, Shigenori
    Kinoshita, Yoshimi
    Nakagawa, Yuki
    Akai, Miku
    Ookura, Mari
    Uemura, Shinobu
    Yamaguchi, Kazuyuki
    Nomura, Shosaku
    INTERNAL MEDICINE, 2009, 48 (05) : 387 - 388